Where Atara Biotherapeutics Stands With Analysts Over the past 3 months, 4 analysts have published their opinion on Atara Biotherapeutics (NASDAQ:ATRA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Benzinga · May 24, 2022
HC Wainwright & Co. Maintains Buy Rating for Atara Biotherapeutics: Here's What You Need To Know HC Wainwright & Co. has decided to maintain its Buy rating of Atara Biotherapeutics (NASDAQ:ATRA) and lower its price target from $31.00 to $29.00. Shares of Atara Biotherapeutics are trading down 3.1% over the last 24 hours, at $5.00 per share. Benzinga · May 23, 2022
Atara Biotherapeutics Earnings Preview Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Atara Biotherapeutics will report an earnings per share (EPS) of $-0.98. Benzinga · May 4, 2022
Atara Biotherapeutics Earnings Perspective: Return On Capital Employed Benzinga Pro data, Atara Biotherapeutics (NASDAQ:ATRA) reported Q4 sales of $7.55 million. Earnings fell to a loss of $93.35 million, resulting in a 10.26% decrease from last quarter. Benzinga · Mar 2, 2022
Preview: Atara Biotherapeutics's Earnings Atara Biotherapeutics (NASDAQ:ATRA) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Atara Biotherapeutics will report an earnings per share (EPS) of $-0.69. Benzinga · Feb 25, 2022